CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

KMT2A rearrangement (relapsed/refractory AML)

Gene: KMT2A · Type: fusion

Indications: Acute myeloid leukemia

SensitivityResistanceCIViC Context

FDA Sensitivity Assertions

DrugIndicationRecommendationFDA SourceLink
RevumenibAcute myeloid leukemiaINDICATED
FDA Label
Label